We were very excited this Monday to announce a new partnership with APCER Life Sciences, a global provider of safety, medical, regulatory, and technology services to the pharmaceutical industry. Working with the dedicated professionals at APCER will enable us to expand our reach into the safety and pharmacovigilance departments at pharmaceutical companies globally.
On this past Sunday’s 60 Minutes, astronomer Mike Brown made a bold prediction – that within three years the scientific community would identity a new, large 9th planet located in the outermost area of our solar system. Even more astonishing was how certain he was about that prediction, “I would say at this point, I am certain….that’s a rare thing to say – for a prediction for a scientist. And I’m willing to say it.” Mike Brown has some credibility in this area, as he’s the guy who figured out that Pluto wasn’t a planet after all. Maybe it’s his own guilt over breaking every school-kid’s heart that’s driving his prediction, but both his prediction and his certainty really fascinated me. If you haven’t watched the report, I’d urge you to do so (link is here).
Topics: Drug Safety
As 2016 winds down, am I the only one who feels exhausted?
Between pharma-bro inspired drug pricing madness, a political season that felt like a Bravo reality TV show, and Leicester City robbing my beloved Tottenham Hotspur of their first shot at a Premiere League championship in a very long time, I think John Oliver summed up this year best in this video.
In these blog posts we’re often guilty of highlighting the worst in healthcare (see, for example, here, here, and here). That attitude shouldn’t be totally surprising when we started Advera Health Analytics with a mission to correct a glaring problem in the healthcare system – the lack of transparent drug safety and efficacy data. That said, it seems only fair to give credit where it’s due when things go exactly right. This is one of those stories.
Seventy two hours after 2016 Q2 FDA Adverse Event Reporting System (FAERS) data were publicly released by FDA, our RxFilter® process had it standardized and loaded into the Evidex platform. Based on the volume of data in Q2, it looks like we’re well on the way to yet another record year of adverse events reported into FAERS.
Here is a chart of new case reports (including our estimate for full year 2016). Note that these numbers are based on a clean dataset; de-duplicated, primary suspect cases only).
Last December, Stat News wrote a scathing report on the chronic under reporting of clinical trial results. We followed that up in July with our own blog post, highlighting specific under reporting rates we’ve found in just a handful of indications.
Last week the U.S. Surgeon General Vivek Murthy sent a letter to every doctor in the U.S. to warn them of the dangers of opioid addiction. While certainly well intentioned, I have to ask - in this age of technology, is this the best we can do? Why not fax or, even better, send a Western Union cable?
The battle over drug pricing took an interesting turn here in California this week. On the heels of such negative publicity about high priced prescription drugs, giant price spikes for certain medications, and general bad behavior among certain high profile biotech executives, it’s not surprising that regulators and government bodies are starting to weigh in on ways to regulate or control drug price increases.
Topics: drug pricing
As we hit the end of July, it seems that the summer slowdown is in full effect. For every ten emails I send out I get back at least six “out of office” replies. As with any organization focused on building and supporting a client base, it’s hard not to get a little anxious in August when calls aren’t returned, contracts aren’t processed, and just about everything grinds to a halt.
This post was originally published on the BBK Worldwide Blog.
Big Data was a Big Topic at this year’s DIA Annual Meeting, and continues to be an area of interest and investment across the life sciences and healthcare industries as organizations seek to further integrate new data streams and real-time analysis into clinical R&D. Data collection, management and analysis are at the crux of everything we do here at BBK, and our clients are keenly interested in how to manage and optimize Big Data. We interviewed Brian Overstreet, CEO of Advera Health Analytics, a leading healthcare informatics company, to get their take and to see how access to meaningful data is helping to push healthcare forward.